An observational study in Pneumonia, Bronchoalveolar Lavage and Antimicrobial Treatment, sponsored by Azienda Ospedaliero-Universitaria Careggi. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.
Sponsored by Azienda Ospedaliero-Universitaria Careggi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Pneumonia with a site in Italy — 19 open to participants now, 20 under way, 4 of them phase 3. Pneumonia · Italy.
Among the 83 studies in Pneumonia with a site in Italy, this one is the 27th largest by planned enrollment of the 37 observational ones that give a count, is one of 8 that started in 2024, is one of 37 observational ones, reaches primary completion later than 8 of the 19 other live ones, and was the 72nd registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →19 of the 83 studies in Pneumonia with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy
Ages 18–90
Societa Italiana di Pneumologia · Sites in Italy
Ages 18+
Meyer Children's Hospital IRCCS · Sites in Italy, United States, Israel
Ages 3–10
Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica · Sites in Italy
Ages 18–80
University of Bari Aldo Moro · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 16 · Phase 4 1
First in 2003; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 93 is below the median of 255 across 537 observational studies indexed under Pneumonia.
Median enrollment 108 across the 46 interventional studies, 246 across the 37 observational. Of the 38 that completed or were terminated, 10 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 83 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero-Universitaria Careggi is the lead sponsor of 78 studies on the registry; 23 are open to participants now.
Azienda Ospedaliero-Universitaria Careggi has 4 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumonia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06279741EXO Biologics S.A.Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants | 2027-01-31 |
| NCT06511583Azienda Ospedaliero-Universitaria CareggiFBS-ASaP: Fibrobronchoscopy in ASpiration Pneumonia in the Emergency Department | 2027-02-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 83 studies in Pneumonia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective Observational Study (on Diagnostic Procedure) - Single-Center, Non-Profit.
A pilot study will be conducted on a prospective cohort of patients with HCAP (Healthcare-Associated Pneumonia). This study will be conducted on a single arm of patients. No control group or randomization is planned.
The use of syndromic molecular panels in pneumonias with risk factors for MDR (multidrug-resistant) pathogens, such as in patients with HCAP, has become common practice. However, the use of this tool is reserved for patients with severe forms of HCAP (PIRO>2, at least moderate ARDS, and respiratory failure requiring high-flow oxygen during sepsis) (30), and it is not yet standardized by international guidelines. The decision to use this tool or not is currently at the clinician\'s discretion and is usually reserved for the severe forms mentioned above. The study aims to determine if the early use of this tool has a real benefit on the management of antibiotic therapy for these patients in terms of therapeutic changes compared to corporate and international guidelines.
Duration of patient enrollment: 1 year. Duration of the study: 1.5 years.
All patients over the age of 18 who undergo bronchoalveolar lavage (BAL) in the Emergency Department (DEA), with a Rankin score of less than 5, and who are admitted to the Emergency Department with a diagnosis of healthcare-associated pneumonia (HCAP) of bacterial, viral, or fungal origin.
A patient is considered to have HCAP if they meet any of the following conditions:
Hospitalized in an acute care hospital for two or more days within 90 days of symptom onset Residing in a nursing home or long-term care facility Received intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days Attended a hospital or hemodialysis clinic within the past 30 days for medical reasons, visits, or day services
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients over the age of 18 who undergo bronchoalveolar lavage (BAL) in the Emergency Department (DEA), with a Rankin score of less than 5, and who are admitted to the Emergency Department with a diagnosis of healthcare-associated pneumonia (HCAP) of bacterial, viral, or fungal origin. The diagnosis must be confirmed by clinical and radiological criteria according to the IDSA guidelines, which include: New pulmonary infiltrate on chest X-ray, Evidence that the infiltrate is of infectious origin, At least two of the following three clinical signs: Fever higher than 38 °C, Leukocytosis or leukopenia, Purulent secretions.
Additionally, patients must meet at least one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study seeks to assess the utility of molecular diagnostic tests in the emergency department for the microbiological etiological diagnosis of healthcare-associated pneumonia (HCAP). In clinical practice, patients with respiratory and infectious symptoms undergo blood sample collection for blood gas, chemical-physical, and culture analyses, urine samples for urinary antigen testing, and imaging diagnostics (X-ray, CT, ultrasound). Due to local infection control and surveillance measures, all patients with respiratory symptoms undergo a nasopharyngeal antigen test for SARS-CoV-2 as part of standard clinical practice. After completing the diagnostic work-up and diagnosing HCAP pneumonia, endobronchial samples are typically collected for multiplex PCR testing (BIOFIRE® FILMARRAY® Pneumonia plus Panel). Patients from whom these samples are collected are those needing high-flow oxygen therapy (VM35 or FiO2 higher, Reservoir, HFNC, NIV, CPAP), undergoing IOT, SOFA ≥2, PaO2/FiO2 \< 200, o
evaluate the impact of early use of multiplex PCR
The primary objective of the study is to evaluate the impact of early use of multiplex PCR on empirical antibiotic therapy. This will be measured by considering the percentage of cases in which the use of multiplex PCR alters the therapy ('escalation' and 'de-escalation') compared to local empirical antibiotic therapy guidelines within 24 hours of hospital admission.
Time frame: perioperatively/periprocedurally
Time to Antibiotic Escalation or De-escalation
Measure the time from hospital admission to the escalation or de-escalation of antibiotic therapy.
Time frame: up to 3 months
Length of Hospital Stay
Assess the total duration of the hospital stay.
Time frame: up to 3 months
Need for Escalation of Supportive Therapy:
Evaluate the necessity for increased supportive therapy, defined as: a) Need for invasive or non-invasive ventilation b) Transfer to a higher level of care c) In-hospital mortality from any cause (complicated course)
Time frame: up to 3 months
Duration of Antibiotic Therapy:
Track the length of time antibiotics are administered.
Time frame: up to 3 months
De-escalation of Antibiotic Therapy
Assess the de-escalation of antibiotic therapy within the first 7 days of inclusion in the study.
Time frame: 7 days from admission
Escalation of Antibiotic Therapy
Assess the escalation of antibiotic therapy within the first 7 days of inclusion in the study.
Time frame: 7 days from admission
Identification of HCAP Etiology
Determine the cause of HCAP within the first 7 days of inclusion using all methods: multiplex PCR, culture tests, antigen detection, and serology.
Time frame: 7 days from admission
In-hospital Mortality
Measure in-hospital mortality rates for pneumonia and all causes.
Time frame: up to 3 months
30-day Mortality and Readmission
Measure mortality rates for pneumonia and all causes, and track readmissions within 30 days.
Time frame: 30 days from discharge
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jul 2025, 13 months after the start.
Of 210 non-industry observational studies under Pneumonia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 13 months is below that.
Counting every sponsor, half of 223 studies reached it within 27 months; a quarter within 13 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria Careggi